Olsalazine Knowpia

Olsalazine
Clinical data
Trade names	Dipentum
AHFS/Drugs.com	Monograph
MedlinePlus	a601088
License data	US DailyMed: Olsalazine;
Pregnancy; category	AU: C; ;
Routes of; administration	By mouth
ATC code	A07EC03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Protein binding	99%
Elimination half-life	0.9 hours
Identifiers
CAS Number	15722-48-2 ;
PubChem CID	22419;
DrugBank	DB01250 ;
ChemSpider	10642377 ;
UNII	ULS5I8J03O;
KEGG	D08295 ; as salt: D00727 ;
ChEMBL	ChEMBL425 ;
CompTox Dashboard (EPA)	DTXSID8023391 ;
ECHA InfoCard	100.116.494
Chemical and physical data
Formula	C14H10N2O6
Molar mass	302.242 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)c1cc(ccc1O)/N=N/c2cc(C(O)=O)c(O)cc2;
	InChI InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+ ; Key:QQBDLJCYGRGAKP-FOCLMDBBSA-N ;
	(what is this?) (verify)

Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis.^[2]^[3] It is sold under the brand name Dipentum.^[4]

Olsalazine itself is a pro-drug of mesalazine (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by azoreductases produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production.^[4]

History edit

Olsalazine gained Food and Drug Administration (FDA) approval in 1990.

Supply edit

The drug is supplied by UCB Pharma.

Research edit

In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine, for trials the following year.^[5]

References edit

^ ^a ^b "Olsalazine (Dipentum) Use During Pregnancy". Drugs.com. 6 September 2019. Retrieved 9 October 2020.
^ "Olsalazine--a further choice in ulcerative colitis". Drug and Therapeutics Bulletin. 28 (15): 57–8. July 1990. doi:10.1136/dtb.28.15.57. PMID 2131213. S2CID 7178709.
^ Wadworth AN, Fitton A (April 1991). "Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease". Drugs. 41 (4): 647–64. doi:10.2165/00003495-199141040-00009. PMID 1711964. S2CID 243654426.
^ ^a ^b "Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 9 January 2021.
^ "Giaconda gets European patent for drug". The Sydney Morning Herald. 28 December 2006. Retrieved 16 January 2021.

[Drugs.com_pregnancy-1] "Olsalazine (Dipentum) Use During Pregnancy". Drugs.com. 6 September 2019. Retrieved 9 October 2020.

[pmid2131213-2] "Olsalazine--a further choice in ulcerative colitis". Drug and Therapeutics Bulletin. 28 (15): 57–8. July 1990. doi:10.1136/dtb.28.15.57. PMID 2131213. S2CID 7178709.

[pmid1711964-3] Wadworth AN, Fitton A (April 1991). "Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease". Drugs. 41 (4): 647–64. doi:10.2165/00003495-199141040-00009. PMID 1711964. S2CID 243654426.

[Med1-4] "Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 9 January 2021.

[5] "Giaconda gets European patent for drug". The Sydney Morning Herald. 28 December 2006. Retrieved 16 January 2021.

[2]

[3]

[4]

[1]

[5]

Summary

History edit

Supply edit

Research edit

References edit